Table of Contents
PERSONAL PROTECTIVE EQUIPMENT (PPE) INSTRUCTIONAL VIDEOS
- High Risk PPE (English)
- High Risk PPE (French)
- Low Risk PPE (English)
- Low Risk PPE (French)
Ebola Virus Disease (EVD)
Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness caused by Ebola virus. EVD has a case fatality rate of up to 90%. It is one of the world's most virulent diseases.
The virus is transmitted by direct contact with the blood, body fluids and tissues of infected animals or people. Severely ill patients require intensive supportive care. During an outbreak, those at higher risk of infection are health workers, family members and others in close contact with sick people and deceased patients. Ebola virus is not airborne, but may be spread via droplets that are coughed or sneezed from a sick person and enter the eyes, nose, or mouth of another person who is less than two metres away.
Epidemiology
Summary of epidemiological facts and experience to date: [ref: WHO]
|
For more information refer to:
Surveillance
[Ref: PHAC]
EVD has been nationally notifiable in Canada since 2000. As a nationally notifiable disease, ebolavirus cases are reported to the Public Health Agency of Canada through national surveillance systems. The Agency also works closely with its national and international partners, including the World Health Organization, to track EVD outbreaks.
Health care workers in Canada should be vigilant for persons with symptoms compatible with EVD and who have returned from affected countries within 21 days of symptom onset.
A person with EVD-compatible symptoms is defined as an individual presenting with fever (temperature ≥ 38.0 degrees Celsius) OR at least one of the following symptoms/signs:
Epidemiological Risk Factors:
Person Under investigation (PUI) A person with EVD-compatible symptoms (as defined above) AND EVD has not been ruled out.
Confirmed Case A person with laboratory confirmation of EVD infection using at least one of the methods below:
|
For more information on EVD surveillance:
- National Case Definition: Ebola virus disease (EVD) (PHAC)
- EVD Case Report Form (PHAC)
- Ebola and Marburg Virus Outbreak Toolkit (WHO)
Signs and Symptoms
EVD is a severe acute viral illness often characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function. Bleeding from gums, nose, injection sites and gastrointestinal tract occurs in about 50% of patients. Dehydration and significant wasting occur as the disease progresses. Laboratory findings include low white blood cell and platelet counts and elevated liver enzymes.
People are infectious as long as their blood and secretions contain the virus. The incubation period is 2 to 21 days. Other diseases that should be ruled out before a diagnosis of EVD can be made include: malaria, typhoid fever, shigellosis, cholera, leptospirosis, plague, rickettsiosis, relapsing fever, meningitis, hepatitis and other viral haemorrhagic fevers.
There is no effective antiviral treatment for ebolavirus infections. Treatment is supportive, and is directed at maintaining renal function and electrolyte balance, and at combatting haemorrhage and shock.
Infection Prevention and Control
For health care providers in Canada: [Ref: PHAC]
- Ebola virus is transmitted by direct contact (e.g., through broken skin or mucous membranes) with the blood or other body fluids (e.g., stool, urine, saliva, semen) of an infected individual and/or indirectly through contact with environmental surfaces and fomites contaminated with body fluids. Airborne transmission has not been documented.
- The incubation period of EVD varies from 2 to 21 days. Cases are not considered to be communicable before the onset of symptoms but communicability increases with each subsequent stage of illness and the case remains communicable as long as blood and body fluids secretions contain the virus. This includes the post-mortem period.
- Use Contact and Droplet Precautions, in addition to Routine Practices, in settings where contact with patients suspected or confirmed to have EVD is anticipated. The need for enhanced PPE (e.g., double gloving, leg and shoe coverings, hair/head covering) is determined by assessing the risk of heavy exposure to blood and body fluids.
- The effectiveness of PPE (gowns, gloves, masks, facial protection, respirators) is highly dependent on appropriate selection and proper use, including correct technique and sequence for putting on and taking off PPE, discarding into designated receptacles, and hand hygiene to minimize risk of transmission
- In health care settings when aerosol generating medical procedures must be performed on suspected or confirmed EVD patients, strategies to reduce aerosol generation must also be implemented.
PERSONAL PROTECTIVE EQUIPMENT (PPE) INSTRUCTIONAL VIDEOS
The following training videos are a joint collaboration between Health Canada, the Royal College of Physicians and Surgeons of Canada, the Public Health Agency of Canada and IPAC Canada
- High Risk PPE (English)
- High Risk PPE (French)
- Low Risk PPE (English)
- Low Risk PPE (French)
Donning & Doffing of Personal Protective Equipment (PPE) (Medscape)
- PPE: Clinically Stable Patients Suspected to have VHF (CDC)
- PPE: Confirmed Patients and Clinically Unstable Patients Suspected to have VHF (CDC)
- Donning & Doffing of Personal Protective Equipment (PPE) (Medscape)
Vaccines
-
To date, at least 15 vaccines are being developed (in North America, Europe, Russia and China), with four main candidates in varying advanced stages of human testing. The two lead vaccine candidates started human clinical trials in September 2014 and data on their safety and immunogenicity profiles were ready by December-January, breaking all records in terms of vaccine trial Phase I timelines. WHO played a key role in this endeavour, by identifying and coordinating numerous trial sponsors to test the vaccines contemporaneously in the US, Canada, and several countries in Europe and Africa.
- Ebola Virus Vaccine: Canadian Immunization Guide (PHAC)
- Ebola Virus Vaccines (WHO)
|
More information:
Laboratory Information and Specimen Collection
[Ref: PHAC]
Samples from patients are an extreme biohazard risk. Testing for Ebola virus should be conducted under maximum biological containment conditions.
The Public Health Agency's National Microbiology Laboratory (NML) is the only facility in Canada that can work with live haemorrhagic fever viruses such as Ebola virus. The NML offers the world's highest level of containment and meets or exceeds all national and international guidelines for safety and security.
Health professionals should not undertake any laboratory testing on a patient suspected of having EVD or any other viral haemorrhagic fever infection.
If a sample requires testing, immediately contact the Agency's 24-hour emergency line: 1-800-545-7661. An expert will assist you in developing an Emergency Response Assistance Plan for the safe shipping of the sample to the Agency's NML.
Travel Advice
It is recommended that Canadians should practice special health precautions, such as receiving additional vaccinations. A notice at this level would be issued if there is an outbreak in a limited geographic location, a newly identified disease in the region or a change in the existing pattern of disease (Level 2 Travel Warning)
The risk of a tourist or businessman/woman becoming infected with Ebola virus during a visit to the affected areas and developing disease after returning is extremely low, even if the visit included travel to the local areas from which primary cases have been reported. Transmission requires direct contact with blood, secretions, organs or other body fluids of infected living or dead persons or animals, all unlikely exposures for the average traveller. Tourists are in any event advised to avoid all such contacts. [Ref: WHO]
- Travel Health Notices (PHAC)
Ebola Links
Public Health Agency of Canada (PHAC) |
- Ebola Virus Disease
- National Case Definition: Ebola virus disease (EVD)
- EVD Case Report Form
- Ebola virus disease: Prevention and Risks
- Monitoring Ebola Virus Disease
- Ebola Virus Disease: Symptoms and Treatment
- Infection Prevention and Control Measures for Ebola in Acute Care Settings
- Interim Biosafety Guidelines for Laboratories Handling Specimens from Patients Under Investigation for Ebola Virus Disease
- Environmental Sanitation Practices to Control the Spread of Communicable Disease in Passenger Conveyances and Terminals (2014)
- Public Health Management of Cases and Contacts of Ebola Virus Disease in the Community Setting in Canada (EVD)
- Interim Guidance for Airline Cabin Crews, Cleaning Personnel and Cargo Personnel: How to Protect Yourself and Others from Ebola Virus Disease
- Ebola virus disease: For health professionals and humanitarian aid workers
- Travel Health Notices (PHAC)
World Health Organization (WHO) |
- General Information on Ebola
- Fact Sheet on Ebolavirus Disease
- WHO Disease Outbreak News
- WHO Situation Reports
- Ebola Response Roadmap
- Ebola and Marburg disease outbreaks: infection prevention and control research priorities in health care settings (2024)
- Infection prevention and control guideline for Ebola and Marburg disease (2023)
- Frequently Asked Questions on Ebola Virus Disease (2017)
- Infection Prevention and Control Guidance for Care of Patients in Health-Care Settings, with Focus on Ebola (2014)
- How to conduct safe and dignified burial of a patient who has died from suspected or confirmed Ebola virus disease (2017)
- Updated personal protective equipment guidelines: Personal protective equipment in the context of filovirus disease outbreak response (2014)
- Personal protective equipment for use in a filovirus disease outbreak- Rapid advice guideline (2016)
- Publications, technical guidance on Ebola (2018)
- Steps to Putting on Personal Protective Equipment
- Steps to Taking off Personal Protective Equipment
Centers for Disease Control (CDC) |
- General Information on Ebola Virus Disease
-
Infection Prevention and Control Recommendations for Patients in U.S. Hospitals who are Suspected or Confirmed to have Selected Viral Hemorrhagic Fevers (VHF) - VHF -Guidance for Personal Protective Equipment (PPE)
- PPE: Clinically Stable Patients Suspected to have VHF
- PPE: Confirmed Patients and Clinically Unstable Patients Suspected to have VHF
- VHF-PPE FAQs
- VHF: Interim Guidance for Environmental Infection Control in Hospitals
- Handling VHF-Associated Waste
- Safe Handling of Human Remains of VHF Patients in U.S. Hospitals and Mortuaries
Provincial |
British Columbia
- General Information on Ebola
- Statement on Ebola Virus Disease (30 July 2014)
- Guidance for BC Health Professionals
Manitoba
Alberta
- Ebola Information
- Infection Prevention and Control (IPC) & Workplace Health and Safety (WHS) Ebola Virus Disease (Ebola) Guidance for Acute Care Settings (22 Oct 2014)
- Emergency Department and Urgent Care Centre Ebola Clinical Assessment tool (for Physicians and Nurse Practitioners) (30 Oct 2014)
- Emergency Department and Urgent Care Centre Ebola Triage Protocol (Screening & Rapid Assessment at presentation to ED/UCC) (22 Oct 2014)
- Care of the Seriously or Critically Ill Patient with Possible or Proven Ebola Virus Disease (Version 11) (27 Oct 2014)
- Suspect/Confirmed Ebola Virus Disease Contact and Droplet Precautions (17 Oct 2014)
- PPE:
- PPE Requirements for Suspect/Confirmed Ebola Virus Disease (17 Oct 2014)
- WET Patient: Donning Personal Protective Equipment (16 Oct 2014)
- WET Patient: Doffing Personal Protective Equipment (16 Oct 2014)
- Dry Patient: Donning Personal Protective Equipment (16 Oct 2014)
- Dry Patient: Doffing Personal Protective Equipment (16 Oct 2014)
- Ebola Waste Management Recommendations (22 Oct 2014)
- Deceased Body: Acute Care Setting Algorithm (DB-AC) (30 Oct 2014)
- Body Handling Protocol (BHP) (30 Oct 2014)
New Brunswick
Newfoundland/Labrador
Nova Scotia
Ontario
- Laboratory Guidance -Viral Haemorrhagic Fevers including Ebola Virus Disease -Public Health Ontario (April 2019)
- Viral Haemorrhagic Fever including Ebola Virus Disease -Public Health Ontario (May 2019)
- Guidance for Patients with Suspect or Confirmed Viral Haemorrhagic Fevers (VHF) in Acute Care Settings -Public Health Ontario (July 2016)
- Management of Ebola virus disease (EVD) survivors in Ontario (July 2016)
- Ebola Virus Disease (EVD) - Public Health Ontario
- Ebola Virus Disease - Emergency Management
Other Links |
- APIC: Ebola Infection Prevention and Control Resources
- University of Nebraska Medical Centre: Donning PPE/ Doffing PPE
- Médecins Sans Frontières (Doctors without Borders): Filovirus Haemorrhagic Fever Guideline, 2008
- Published Articles (EID) and Podcasts on Ebolavirus
- Medscape: Donning & Doffing of Personal Protective Equipment (PPE)